DK1230243T3 - Polycycloalkylpuriner som adenosinreceptorantagonister - Google Patents

Polycycloalkylpuriner som adenosinreceptorantagonister

Info

Publication number: DK1230243T3
Authority: DK; Denmark
Prior art keywords: polycycloalkylpurines; receptor antagonists; adenosine receptor; adenosine; disorders
Prior art date: 1999-11-12

Application number

DK00978546T

Other languages

English (en)

Inventor

James E Dowling

Carol L Ensinger

Gnanasambandam Kumaravel

Russell C Petter

William F Kiesman

Ko Chung Lin

He Xi Chang

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-13

Publication date

2009-06-15

2000-11-13 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2009-06-15 Application granted granted Critical

2009-06-15 Publication of DK1230243T3 publication Critical patent/DK1230243T3/da

Links

229940121359 adenosine receptor antagonist Drugs 0.000 title 1
239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
108010060263 Adenosine A1 Receptor Proteins 0.000 abstract 1
102000030814 Adenosine A1 receptor Human genes 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
239000002598 adenosine A1 receptor antagonist Substances 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK00978546T 1999-11-12 2000-11-13 Polycycloalkylpuriner som adenosinreceptorantagonister DK1230243T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16519199P	1999-11-12	1999-11-12
PCT/US2000/031058 WO2001034610A1 (en)	1999-11-12	2000-11-13	Polycycloalkylpurines as adenosine receptor antagonists

Publications (1)

Publication Number	Publication Date
DK1230243T3 true DK1230243T3 (da)	2009-06-15

Family

ID=22597852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00978546T DK1230243T3 (da)	1999-11-12	2000-11-13	Polycycloalkylpuriner som adenosinreceptorantagonister

Country Status (35)

Country	Link
US (5)	US6649600B1 (da)
EP (3)	EP2070930A1 (da)
JP (1)	JP2003513982A (da)
KR (2)	KR20080027971A (da)
CN (2)	CN101255162A (da)
AT (1)	ATE424403T1 (da)
AU (1)	AU784556B2 (da)
BG (1)	BG65720B1 (da)
BR (1)	BR0015545A (da)
CA (1)	CA2390496A1 (da)
CY (1)	CY1110512T1 (da)
CZ (1)	CZ20021614A3 (da)
DE (1)	DE60041710D1 (da)
DK (1)	DK1230243T3 (da)
EA (1)	EA005211B1 (da)
EE (1)	EE05365B1 (da)
ES (1)	ES2323357T3 (da)
GE (1)	GEP20043303B (da)
HK (1)	HK1049155B (da)
IL (1)	IL149487A0 (da)
IS (1)	IS6379A (da)
ME (1)	MEP42208A (da)
MX (1)	MXPA02004796A (da)
NO (1)	NO328956B1 (da)
NZ (2)	NZ527917A (da)
PL (1)	PL206890B1 (da)
PT (1)	PT1230243E (da)
RS (1)	RS50381B (da)
SI (1)	SI1230243T1 (da)
SK (1)	SK287311B6 (da)
TR (1)	TR200201260T2 (da)
TW (1)	TWI272270B (da)
UA (1)	UA77391C2 (da)
WO (1)	WO2001034610A1 (da)
ZA (1)	ZA200203701B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ527917A (en) *	1999-11-12	2005-03-24	Biogen Inc	Polycycoalkylpurines as adenosine receptor antagonists
IL149486A0 (en) *	1999-11-12	2002-11-10	Biogen Inc	Purine derivatives and pharmaceutical compositions containing the same
UA80258C2 (en) *	2001-09-06	2007-09-10	Biogen Inc	Methods of treating pulmonary disease
DE10145193C1 (de)	2001-09-13	2003-03-13	Sachtler Gmbh & Co Kg	Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
UA84404C2 (ru) *	2002-06-12	2008-10-27	Байоджен Айдек Ма Инк.	Способ лечения ишемического реперфузионного повреждения с помощью антагонистов рецептора аденозина
WO2004009091A1 (en)	2002-06-17	2004-01-29	Glaxo Group Limited	Purine derivatives as liver x receptor agonists
WO2004009594A2 (en) *	2002-07-19	2004-01-29	Aryx Therapeutics	Xanthine derivatives having adenosine a1-receptor antagonist properties
JP2006518390A (ja) *	2003-02-19	2006-08-10	エンダシア，インコーポレイテッド	Ａ１アデノシンレセプターアンタゴニスト
US20040229901A1 (en) *	2003-02-24	2004-11-18	Lauren Otsuki	Method of treatment of disease using an adenosine A1 receptor antagonist
CN1859913A (zh) *	2003-04-25	2006-11-08	美国诺华卡迪亚公司	改善肾功能损伤个体多尿症的方法
EP1636229A4 (en)	2003-06-06	2008-07-30	Endacea Inc	ADENOSINE A1 RECEPTOR ANTAGONISTS
MX2007015863A (es)	2005-06-17	2008-04-02	Apogee Biotechnology Corp	Inhibidores de esfingosina cinasa.
WO2007059330A2 (en) *	2005-11-17	2007-05-24	Medkura Inc.	Cubane nucleoside analogs
CA2648281A1 (en) *	2006-04-06	2007-10-18	Novacardia, Inc.	Co-administration of adenosine a1 receptor antagonists and anticonvulsants
CN101085785B (zh) *	2006-06-06	2011-09-21	中国科学院上海药物研究所	用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
JP2009540003A (ja) *	2006-06-16	2009-11-19	ノヴァカーディア，インク．	Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
JP2009543870A (ja) *	2006-07-17	2009-12-10	タイラテック，インク．	昆虫防除のための組成物および方法
WO2008121882A1 (en) *	2007-03-29	2008-10-09	Novacardia, Inc.	Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) *	2007-03-29	2008-10-09	Novacardia, Inc.	Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
JP5603248B2 (ja)	2007-12-21	2014-10-08	エンダセア，インコーポレイテッド	Ａ１アデノシン受容体アンタゴニスト
WO2009152458A1 (en) *	2008-06-13	2009-12-17	Biogen Idec Ma Inc.	Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
WO2010011917A1 (en) *	2008-07-25	2010-01-28	Glaxosmithkline Llc	SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en)	2009-11-19	2011-05-26	Biogen Idec Ma Inc	Novel synthetic methods
AU2010327316B2 (en) *	2009-12-04	2014-10-16	Commonwealth Scientific And Industrial Research Organisation	Polymeric materials
CN101709034B (zh) *	2009-12-14	2017-05-31	大连九信精细化工有限公司	双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
TWI538905B (zh) *	2010-12-22	2016-06-21	Ｈ朗德貝克公司	雙環［３．２．１］辛基醯胺衍生物及其用途
JP2014518267A (ja)	2011-06-27	2014-07-28	杏林製薬株式会社	細菌感染症の治療のための架橋二環式化合物
BR112015021386A2 (pt) *	2013-03-14	2017-07-18	Bristol Myers Squibb Co	moduladores de ácido biciclo [2.2.2] gpr120
US8962660B2 (en)	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators
LT6401B (lt)	2015-07-28	2017-06-12	Vilniaus Universitetas	Karboanhidrazės selektyvūs inhibitoriai
WO2017127306A1 (en)	2016-01-18	2017-07-27	Arisan Therapeutics	Adamatane derivatives for the treatment of filovirus infection
WO2018075301A1 (en)	2016-10-19	2018-04-26	Eastman Chemical Company	Synthesis of bicyclo(2.2.2)octanes
US11548893B2 (en)	2017-07-15	2023-01-10	Arisan Therapeutics Inc.	Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
MY202326A (en)	2017-09-14	2024-04-24	Daiichi Sankyo Co Ltd	Compound having cyclic structure
CN111433181B (zh)	2017-10-11	2023-08-04	伊士曼化工公司	双环[2.2.2]辛烷衍生物的合成
JP7212693B2 (ja)	2017-11-01	2023-01-25	ブリストル－マイヤーズスクイブカンパニー	ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
JP7412424B2 (ja)	2018-09-18	2024-01-12	ブリストル－マイヤーズスクイブカンパニー	Ｌｐａアンタゴニストとしてのオキサビシクロ酸
US10836899B2 (en)	2018-12-13	2020-11-17	Eastman Chemical Company	Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0011399A1 (en) *	1978-11-11	1980-05-28	FISONS plc	N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE3843117A1 (de)	1988-12-22	1990-06-28	Boehringer Ingelheim Kg	Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) *	1989-09-01	1994-03-01	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
JPH06102662B2 (ja) *	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
CA2028235C (en)	1989-10-20	1997-01-21	Fumio Suzuki	Condensed purine derivatives
DE4019892A1 (de)	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
CA2061544A1 (en)	1991-02-25	1992-08-26	Fumio Suzuki	Xanthine compounds
JPH0559056A (ja) *	1991-02-25	1993-03-09	Kyowa Hakko Kogyo Co Ltd	キサンチン誘導体
JPH04270222A (ja) *	1991-02-25	1992-09-25	Kyowa Hakko Kogyo Co Ltd	脳機能改善剤
JPH04346986A (ja) *	1991-05-23	1992-12-02	Kyowa Hakko Kogyo Co Ltd	トリチウム標識化されたキサンチン誘導体
JP3115128B2 (ja) *	1991-11-08	2000-12-04	協和醗酵工業株式会社	キサンチン誘導体
EP0541120B1 (en)	1991-11-08	1999-05-26	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives for the treatment of dementia
EP0556778A3 (en) *	1992-02-17	1993-11-24	Kyowa Hakko Kogyo Kk	Xanthine derivatives
US5342841A (en) *	1992-03-12	1994-08-30	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
JPH0616668A (ja) *	1992-03-12	1994-01-25	Kyowa Hakko Kogyo Co Ltd	キサンチン誘導体
TW252044B (da) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
US5384176A (en) *	1992-12-11	1995-01-24	Zimmerman; Richard C.	Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (fr) *	1993-01-26	1994-08-04	Kyowa Hakko Kogyo Co., Ltd.	Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) *	1993-04-07	1995-03-07	Kyowa Hakko Kogyo Co., Ltd.	8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) *	1993-04-07	2005-12-21	協和醗酵工業株式会社	キサンチン誘導体
US5446046A (en) *	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
AU7675598A (en) *	1997-06-16	1999-01-04	Kyowa Hakko Kogyo Co. Ltd.	Hepatic edema remedy
AU7675498A (en) *	1997-06-16	1999-01-04	Kyowa Hakko Kogyo Co. Ltd.	Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) *	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1999055339A1 (en)	1998-04-24	1999-11-04	Biogen, Inc.	Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
EP0955301A3 (en) *	1998-04-27	2001-04-18	Pfizer Products Inc.	7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
AU4396899A (en)	1998-07-02	2000-01-24	Kyowa Hakko Kogyo Co. Ltd.	Remedies for diabetes
IL149486A0 (en) *	1999-11-12	2002-11-10	Biogen Inc	Purine derivatives and pharmaceutical compositions containing the same
NZ527917A (en) *	1999-11-12	2005-03-24	Biogen Inc	Polycycoalkylpurines as adenosine receptor antagonists
DE60304911D1 (de) *	2002-02-25	2006-06-08	Eisai Co Ltd	Xanthin-Derivate als DPP-IV-Inhibitoren
WO2004009594A2 (en) *	2002-07-19	2004-01-29	Aryx Therapeutics	Xanthine derivatives having adenosine a1-receptor antagonist properties
US7129239B2 (en) *	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
CA2556073C (en) *	2004-02-14	2012-01-10	Smithkline Beecham Corporation	8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators

2000
- 2000-11-13 NZ NZ527917A patent/NZ527917A/en not_active IP Right Cessation
- 2000-11-13 NZ NZ519426A patent/NZ519426A/en not_active IP Right Cessation
- 2000-11-13 EE EEP200200247A patent/EE05365B1/xx not_active IP Right Cessation
- 2000-11-13 UA UA2002064822A patent/UA77391C2/uk unknown
- 2000-11-13 TR TR2002/01260T patent/TR200201260T2/xx unknown
- 2000-11-13 RS YUP-338/02A patent/RS50381B/sr unknown
- 2000-11-13 CZ CZ20021614A patent/CZ20021614A3/cs unknown
- 2000-11-13 PT PT00978546T patent/PT1230243E/pt unknown
- 2000-11-13 EP EP09151275A patent/EP2070930A1/en not_active Withdrawn
- 2000-11-13 SI SI200031029T patent/SI1230243T1/sl unknown
- 2000-11-13 EA EA200200560A patent/EA005211B1/ru not_active IP Right Cessation
- 2000-11-13 EP EP10183076A patent/EP2305684A1/en not_active Withdrawn
- 2000-11-13 DE DE60041710T patent/DE60041710D1/de not_active Expired - Lifetime
- 2000-11-13 AU AU16000/01A patent/AU784556B2/en not_active Ceased
- 2000-11-13 MX MXPA02004796A patent/MXPA02004796A/es active IP Right Grant
- 2000-11-13 CN CNA2008100921415A patent/CN101255162A/zh active Pending
- 2000-11-13 EP EP00978546A patent/EP1230243B1/en not_active Expired - Lifetime
- 2000-11-13 KR KR1020087005528A patent/KR20080027971A/ko not_active Withdrawn
- 2000-11-13 CA CA002390496A patent/CA2390496A1/en not_active Abandoned
- 2000-11-13 PL PL356033A patent/PL206890B1/pl not_active IP Right Cessation
- 2000-11-13 SK SK663-2002A patent/SK287311B6/sk not_active IP Right Cessation
- 2000-11-13 DK DK00978546T patent/DK1230243T3/da active
- 2000-11-13 ME MEP-422/08A patent/MEP42208A/xx unknown
- 2000-11-13 US US09/711,543 patent/US6649600B1/en not_active Expired - Fee Related
- 2000-11-13 CN CNB008164398A patent/CN100390178C/zh not_active Expired - Fee Related
- 2000-11-13 KR KR1020027006093A patent/KR100863761B1/ko not_active Expired - Fee Related
- 2000-11-13 WO PCT/US2000/031058 patent/WO2001034610A1/en not_active Ceased
- 2000-11-13 GE GE4819A patent/GEP20043303B/en unknown
- 2000-11-13 JP JP2001537323A patent/JP2003513982A/ja active Pending
- 2000-11-13 IL IL14948700A patent/IL149487A0/xx not_active IP Right Cessation
- 2000-11-13 AT AT00978546T patent/ATE424403T1/de active
- 2000-11-13 HK HK02109310.2A patent/HK1049155B/en not_active IP Right Cessation
- 2000-11-13 ES ES00978546T patent/ES2323357T3/es not_active Expired - Lifetime
- 2000-11-13 BR BR0015545-4A patent/BR0015545A/pt not_active Application Discontinuation
- 2000-12-15 TW TW089123845A patent/TWI272270B/zh active
2002
- 2002-05-09 ZA ZA200203701A patent/ZA200203701B/xx unknown
- 2002-05-10 NO NO20022238A patent/NO328956B1/no not_active IP Right Cessation
- 2002-05-10 IS IS6379A patent/IS6379A/is unknown
- 2002-05-31 BG BG106762A patent/BG65720B1/bg unknown
2003
- 2003-08-21 US US10/646,454 patent/US20040067966A1/en not_active Abandoned
2006
- 2006-07-10 US US11/484,805 patent/US7579354B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/487,764 patent/US20070015732A1/en not_active Abandoned
2009
- 2009-02-10 US US12/368,469 patent/US20090221821A1/en not_active Abandoned
- 2009-05-21 CY CY20091100543T patent/CY1110512T1/el unknown

Also Published As

Publication number	Publication date
HK1049155A1 (en)	2003-05-02
US20070015732A1 (en)	2007-01-18
EP2070930A1 (en)	2009-06-17
DE60041710D1 (de)	2009-04-16
TR200201260T2 (tr)	2002-09-23
US20060252730A1 (en)	2006-11-09
US20090221821A1 (en)	2009-09-03
BR0015545A (pt)	2002-08-06
BG106762A (en)	2003-01-31
SK6632002A3 (en)	2003-02-04
PT1230243E (pt)	2009-06-12
AU1600001A (en)	2001-06-06
EA200200560A1 (ru)	2002-10-31
US20040067966A1 (en)	2004-04-08
GEP20043303B (en)	2004-01-12
EP1230243A1 (en)	2002-08-14
RS50381B (sr)	2009-11-10
WO2001034610A1 (en)	2001-05-17
EP1230243B1 (en)	2009-03-04
KR20020049050A (ko)	2002-06-24
NZ527917A (en)	2005-03-24
KR100863761B1 (ko)	2008-10-16
SK287311B6 (sk)	2010-06-07
MXPA02004796A (es)	2007-01-30
US6649600B1 (en)	2003-11-18
JP2003513982A (ja)	2003-04-15
MEP42208A (en)	2011-02-10
SI1230243T1 (sl)	2009-08-31
NO20022238L (no)	2002-07-12
EP2305684A1 (en)	2011-04-06
NO328956B1 (no)	2010-06-28
IL149487A0 (en)	2002-11-10
NO20022238D0 (no)	2002-05-10
ZA200203701B (en)	2004-02-23
PL356033A1 (en)	2004-06-14
AU784556B2 (en)	2006-05-04
CY1110512T1 (el)	2015-04-29
BG65720B1 (bg)	2009-08-31
EE05365B1 (et)	2010-12-15
YU33802A (sh)	2006-01-16
CN101255162A (zh)	2008-09-03
NZ519426A (en)	2003-08-29
EE200200247A (et)	2003-06-16
CN1402729A (zh)	2003-03-12
ATE424403T1 (de)	2009-03-15
UA77391C2 (en)	2006-12-15
US7579354B2 (en)	2009-08-25
TWI272270B (en)	2007-02-01
CN100390178C (zh)	2008-05-28
CA2390496A1 (en)	2001-05-17
KR20080027971A (ko)	2008-03-28
PL206890B1 (pl)	2010-10-29
CZ20021614A3 (cs)	2002-07-17
HK1049155B (en)	2009-11-06
ES2323357T3 (es)	2009-07-14
IS6379A (is)	2002-05-10
EA005211B1 (ru)	2004-12-30

Publication	Publication Date	Title
NO20022238D0 (no)	2002-05-10	Polycykloalkylpuriner som adenosinreseptorantagonister
CY1106560T1 (el)	2012-01-25	Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
TNSN05045A1 (en)	2007-05-14	Indole or benzimidazole derivatives for modulating ikappab kinase
DK1578740T3 (da)	2007-07-30	1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK1551803T3 (da)	2007-02-19	Azabicycloderivater som muskarine receptorantagonister
GB9815618D0 (en)	1998-09-16	Treatment of dyskinesia
WO2002018379A3 (en)	2002-07-25	7-oxo pyridopyrimidines
DE69834500D1 (de)	2006-06-14	Xanthinderivative zur behandlung von hirnischämie
ATE256126T1 (de)	2003-12-15	5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
NZ533358A (en)	2007-05-31	3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
PT889044E (pt)	2005-01-31	Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE321044T1 (de)	2006-04-15	C-6 ringsubstituierte pyrido(1,2- a)benzimidazolderivate zur behandlung von störungen des zentralen nervensystems
NO20053612L (no)	2005-09-23	1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet